News & Events

Toft Group Completes Executive Search for Vice President, Business Development for Inivata in Research Triangle Park, NC

Executive search firm Toft Group has placed Thomas Schlumpberger, PhD, as Vice President of Business Development for Inivata in Research Triangle Park, NC.

Dr. Schlumpberger was previously Head of Diagnostic Business and Vice President, Diagnostics with Singulex. Prior to that, he held leadership positions at Annai Systems and AliveCor. Dr. Schlumpberger served as the Chief Commercial Officer at Invitae (f/k/a Locus Development). Earlier in his industry career, Thomas served with Epocal as Senior Vice President of International Sales and Business Development. He currently sits on the board of DxEconomics and serves as Deal Advisor to CroMedX.

Dr. Schlumpberger holds a PhD in Molecular and Cell Biology from the University of California, Berkeley, and an MS in Electrical Engineering and Information Theory from the Technical University, Munich, Germany.

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide.  The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.

About Inivata

Inivata is a global clinical cancer genomics company utilizing a proprietary, industry-leading liquid biopsy platform to transform patient care.  Using a simple blood test (liquid biopsy), the analysis of ctDNA is a new lower-cost, less invasive, highly sensitive method for oncologists to diagnose and monitor cancer progression and treatment. The InVision® liquid biopsy platform is based on pioneering research from the Rosenfeld Lab at the Cancer Research UK Cambridge Institute (CRUK-CI), University of Cambridge, combines industry-leading sensitivity with select multi-gene panels to provide clinically actionable information to clinicians. Inivata has established collaborations with world-leading cancer centers and academic institutions, and is partnering with pharmaceutical and biotechnology companies.  The Company has a CLIA lab in Research Triangle Park, NC and laboratories in Cambridge, UK.

Toft Group Completes Search for Associate Director, Human Resources for Puma Biotechnology, Inc. (NASDAQ: PBYI), in Los Angeles, CA

Executive search firm Toft Group has placed Laci Mayton as Associate Director of Human Resources at Puma Biotechnology, Inc. in Los Angeles, CA.

Ms. Mayton was previously the Human Resource Manager for GenMark Diagnostics. Prior to that, Ms. Mayton was with Thermo Fisher Scientific as Human Resources Manager. Ms. Mayton is a certified human resources professional with a Six Sigma Black Belt. She holds a degree in political science from Sam Houston State University in Texas.

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide.  The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to three drug candidates — PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in July 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Toft Group Completes Search for Senior Vice President, Commercial Operations for Novoheart (TSXV: NVH; FWB: 3NH)

Executive search firm Toft Group has placed Bill Williams, PhD as Senior Vice President, Commercial Operations for Novoheart (TSXV: NVH; FWB: 3NH), a global stem cell biotechnology company.

Dr. Williams has over 20 years of experience in the life science industry spanning business development, sales and marketing. He was most recently Vice President, Global Sales, Marketing and Business Development with Organovo, Inc. He joined Organovo from Aushon Biosystems where he spent 3 years as their Vice President, Global Sales and Marketing. Earlier in his industry career, Dr. Williams held management roles for Ciphergen Biosystems and Beckman Coulter.

Dr. Williams holds a PhD in Analytical Chemistry from Texas A&M University.

About Toft Group Executive Search

Toft Group is a global executive search firm fully devoted to life sciences and healthcare, with a focus on innovation-driven companies working at the intersection of biotech and high tech. Toft Group’s targeted, accurate search process translates into exceptional return-on-investment for clients nationwide.  The team’s extensive relationship network and diversity focus enables Toft Group to present more highly qualified and diverse candidates than clients would otherwise meet. Toft Group excels at quickly filling the hardest to hire leadership roles where talent is limited. The company has offices in the three major U.S. biotech hubs: San Francisco, San Diego, and Boston.

About Novoheart

Novoheart is a global stem cell biotechnology company pioneering an array of next-generation human heart tissue prototypes. It is the first company in the world to have engineered miniature living human heart pumps that can revolutionize drug discovery, helping to save time and money for developing new therapeutics.  Also known as ‘human heart-in-a-jar’, Novoheart’s bio-artificial human heart constructs are created using state-of-the-art and proprietary stem cell and bioengineering approaches and are utilized by drug developers for accurate preclinical testing as to the effectiveness and safety of new drugs, maximizing the successes in drug discovery whilst minimizing costs and harm caused to patients.